Taiho has reupped its commitment to the second fund of Remiges, which focuses on spinouts of Japanese universities.
Remiges Ventures, a US-based venture capital firm focused on pharmaceutical technologies and medical devices developed by Japanese universities, has closed its second fund at $95m.
Limited partners include pharmaceutical groups EA Pharma, Senju Pharmaceutical and Taiho Pharmaceutical, as well as healthcare-focused investment firm 1Globe Capital.
Taiho committed up to $30m for the fund in 2019. It provided the same amount for Remiges’ first vehicle five years earlier, investing alongside peer Sumitomo Dainippon Pharma, and the fund subsequently closed…
